Skip to content
drillr.ai

XNCR

Xencor, Inc.

NASDAQ · USHealthcareBiotechnology
$18.81+7.67%

Price as of Jul 20, 2026

XNCR news

Xencor, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

    Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma -- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune dis

    Business Wire ·

  2. Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

    Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW -- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™ format optimizes bispecifics for treatment of autoimmune diseases; first XenLock™ candidate XmAb412 first-in-human healthy participant study on track for 3Q26 start -- -- Management to host webcast tomorrow, Tuesday, May 5, at

    Business Wire ·